Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - ...

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Wall Street is drawing fresh lines across the large-cap biopharma landscape, initiating coverage on two stocks and maintaining an overweight rating on another.

Shares of Gilead Sciences Inc (NASDAQ: GILD) rallied in early trading on Wednesday after the company reported upbeat fourth-quarter results. Here are the key analyst insights: Check out other analyst ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...